Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Campral receives FDA approval

Aug. 3, 2004

Results of first phase III multicenter study of naltrexone depot formulation

July 22, 2004

Acamprosate does not affect alcohol pharmacokinetics and pharmacodynamics

July 21, 2004

Preliminary data on the effects and safety of TA-NIC in smokers

July 19, 2004

Combined drug therapy reduces cocaine use with limited abuse potential in primates

June 15, 2004

Probuphine completes pilot study for opiate addiction

June 8, 2004

Progress of dopamine D1-selective antagonist lines up milestones for CeNeS

May 28, 2004

ICS-205930 enhances naltrexone-induced suppression of ethanol consumption

May 24, 2004

European Commission broadens Ferriprox indication

May 17, 2004

Baclofen reported to reduce drug use in cocaine-dependent subjects

May 11, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...